PET Imaging for Colorectal, Ovarian, Gastric, Breast, and Pancreatic Cancers
This study is testing a new imaging method called [18F]FPyQCP PET/CT to see how well it can detect certain cancers, including colorectal, ovarian, gastric, invasive lobular breast, and pancreatic cancers. Researchers want to understand how much radiation exposure comes from [18F]FPyQCP and how accurately it can find cancer in the abdomen (peritoneum). You might be able to join if you are between 18 and 80 years old, have one of these cancers, and meet other health requirements. The study aims to enroll 71 participants.
- Study design
- This is a single-arm, open-label study, meaning all participants receive the same intervention and everyone knows what treatment is being given. It aims to enroll 71 participants.
- What's involved
- Participants will have their radiation exposure assessed for up to 360 minutes after receiving [18F]FPyQCP. Diagnostic performance will be assessed until completion of follow-up procedures, up to 42 days post injection.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 42 days after receiving the injection to assess diagnostic performance.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Steven Rowe, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assess radiation dosimetry of [18F]FPyQCP (Cohort A)Up to 360 minutes post injection
Whole body effective dose of a single dose of \[18F\]FPyQCP
- Assess the diagnostic performance of [18F]FPyQCP in the peritoneum (Cohort B)Until completion of follow-up procedures, up to 42 days post injection
Sensitivity and specificity of \[18F\]FPyQCP PET/CT compared to composite standard of truth